Summary Proliferative activities in 181 primary Borrmann type 4 gastric carcinomas were investigated using percentage labelling of proliferating cell nuclear antigen (PCNA) and an argyrophilic nucleolar organiser region (AgNOR) count. Tumours with a high proliferative activity often metastasised to lymph nodes (P<0.01), and these patients had a lower survival rate (P<0.05). A significant correlation was recognised between the PCNA labelling percentage and AgNOR count (r = 0.452, P< 0.001). Cox's regression analysis showed that PCNA labelling percentage is an independent prognostic factor. These results indicate that estimating proliferative activity may be useful in predicting lymph node metastasis and patients' prognosis in cases of Borrmann type 4 gastric carcinoma.
Advanced carcinoma of the stomach can be classified based on Borrmann's criteria into one of four types (1-4) (Borrmann, 1926) . A knowledge of this classification is important for endoscopists, radiologists and surgeons (Borchard, 1990) . Of the Borrmann types of carcinomas, type 4 is a diffuse malignant lesion with indistinct borders, and is usually identified only at a very advanced stage (Maehara et al., 1992a) . The lack of sharp borders can lead to underestimation of the size. As these cancers grow in the plane of the submucosa beneath an otherwise normal mucosa, establishing the histological diagnosis is difficult (Borchad, 1990) . The clinical course is usually unfavourable and the 5 year survival rates are only 0-20% (Furukawa et al., 1988; Maehara et al., 1992a) . Though many investigators have studied this entity from various aspects, the biological characteristics of Borrmann type 4 gastric carcinoma remain an open question.
As it is now feasible to measure proliferative activities of cells in formalin-fixed paraffin-embedded sections of surgical samples, two parameters of proliferative activity, proliferating cell nuclear antigen (PCNA) and argyrophilic nucleolar organiser regions (AgNOR), were measured. PCNA, a 36 kDa non-histone nuclear polypeptide, is an auxiliary protein of DNA polymerase delta , and plays a critical role in the initiation of cell proliferation (Jaskulski et al., 1988) . The levels of PCNA increase in the nucleus during the late GI phase immediately prior to the onset of DNA synthesis, become maximal during the S phase, decline again during G2 and are low in M phase and quiescent cells (Kurki et al., 1987) . Though PCNA staining has limitations in that the molecule has a long half-life which can also lead to staining of cells which have exited from the cycle , it is a useful marker for proliferating cells (McCormick & Hall, 1992) . Nucleolar organiser regions (NORs) are loops of DNA (rDNA) encoded for ribosomal RNA (rRNA) production (Watson et al., 1987) . The proteins associated with the NORs, the so-called AgNOR proteins, are argyrophilic, acidic and non-histone (Fakan & Hernandez-Verdan, 1986 ) and may serve as a marker for rDNA transcription activity or of rDNA transcriptional potential (Dimova et al., 1982; Busch, 1984; Walker, 1988) . Thus, AgNOR staining can also serve as a parameter of proliferation (Egan & Crocker, 1992 Iwanaga et al. (1983) . Adjuvant chemotherapy was given to 171 patients.
Immunohistochemical study for PCNA Sections from paraffin blocks were dewaxed and stained using the avidin-biotin-peroxidase complex method. The primary antibody, PC10, a monoclonal mouse antibody for human PCNA, was purchased from Dako (Carpinteria, CA, USA). The sections were incubated for 2 h with PC1O (dilution 1:20) at room temperature, with biotinylated goat antimouse IgG (1:200 for 30 min; Vector Laboratories), and with the avidin-biotin-peroxidase complex (for 30min; Vector Laboratories). Peroxidase labelling was developed with 3,3'-diaminobenzidine and hydrogen peroxide, and the sections were counterstained with Mayer's haematoxylin.
To ensure consistency of PCNA staining between batches, a known positive control gastric carcinoma was included in each round. Negative controls were included by performing duplicate assays, in one of which the primary antibody was replaced by phosphate-buffered saline.
All of the nuclei stained were regarded as positive for PCNA ( Figure la) . The percentage PCNA labelling was determined by observing 1,000 nuclei in areas of the section with the highest labelling, and the percentage of PCNAlabelfed nuclei was used for analysis. The principal method for determination of heterogeneity was as follows: (1) 
AgNOR staining
From the complete group of 181 patients, 174 tissues were also examined using AgNOR staining. The one-step silver colloid method was used. The NOR staining solution was prepared according to the description of Ploton et al. (1982) (Dixon, 1988 Figure 2 shows the results of linear regression analysis of percentage PCNA labelling and AgNOR count in primary gastric tumours. There was a significant correlation between the percentage PCNA labelling and the AgNOR count (r = 0.452, P<0.001).
Proliferating activity and prognosis
Survival curves for patients with carcinomas in the low and high PCNA labelling groups are shown in Figure 3 . Surgical mortality was excluded in the analysis of survival. In patients with tumours with a high percentage of PCNA labelling survival rates were less favourable than in those with tumours with low labelling (P<0.001).
Of the 181 patients, 28 who underwent curative operation died within 18 months, and 22 patients lived for over 3 years. Multivariate analysis revealed that tumour size, gross appearance, operative curability and percentage PCNA labelling were independent prognostic factors of Borrmann type 4 gastric carcinoma (Table III) .
Discussion
The results of clinical treatment of patients with Borrmann type 4 gastric carcinoma remain poor. The associated lymph node metastasis, invasion into neighbouring structures and peritoneal dissemination present a great challenge for medical care (Furukawa et al., 1988) . Our previous data (Mori et al., 1993) showed that the mean percentage of PCNA labelling of * Borrmann types 3 and 4 gastric carcinoma was 37.6% and that of Borrmann types 1 and 2 was 30.2%. The proliferative activity of invasive type carcinoma (types 3 and 4) was significantly higher than that of localised lesions (types 1 and * 2) (P <0.01). Between types 3 and 4, there is only a slight differences; thus, the proliferative activity of Borrmann type 4 was somewhat higher than that of other types of gastric (Kakeji et al., 1991) . The same trend was recognised even when the study was restricted to Borrmann type 4 carcinoma, and for patients with tumours of high proliferative activity the prognosis was poor. There was a significant relationship between PCNA labelling and AgNOR count; hence these two parameters are probably interdependent. As both factors stain easily and paraffin-embedded tissue sections can be used, either is likely to lead to a better understanding of the proliferative activity of cancer cells.
Lymph node involvement, serosal invasion, peritoneal metastasis and macroscopic subtype have been considered useful prognostic indicators of Borrmann type 4 gastric carcinomas (Nagayo et al., 1974; Furukawa et al., 1988 ). In the current multivariate analysis, tumour size, macroscopic subtype, operative curability and percentage PCNA labelling were independent factors associated with the prognosis. Pro- liferative activity is one of the independent prognostic factors of Borrmann type 4 carcinoma. As for macroscopic subtype, Sowa et al. (1989) found that extensive lymphatic spread was more often recognised in those tumours with giant folds than those without such folds. Iwanaga et al. (1983) found that giant fold type or stenotic type gradually extended to adjacent organs or to the peritoneum, and that the eroded type invaded via lymphatic vessels in a rather short time. In our study, though patients with giant fold-type carcinoma died earlier than those with the eroded type, there was no significant difference in proliferative activity among these macroscopic subtypes. We consider that proliferative activity is an objective factor to predict survival of a patient. By estimating the proliferative activity, the physician can estimate the extent of lymph node metastasis and the prognosis, and can tailor post-operative adjuvant chemotherapy for individual patients. For patients with carcinoma of a high proliferative activity, aggressive adjuvant chemotherapy is the policy in our clinics.
